Neuromedin U: A Myb-regulated autocrine growth factor for human myeloid leukemias

Academic Article


  • The c-myb proto-oncogene has been implicated in leukemogenesis, but possible mechanisms remain ill defined. To gain further insight to this process, we used transcript profiling in K562 cells expressing a dominant-negative Myb (MERT) protein. A total of 105 potential Myb gene targets were identified. Neuromedin U (NmU), a peptide affecting calcium transport, underwent the greatest expression change (∼5-fold decrease). To verify a linkage between c-myb and NmU, their mRNÂ levels were quantitated using real-time polymerase chain reaction in primary acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), as well as normal hematopoietic cells. We found that c-myb was elevated in AML and ALL samples, but NmU expression was increased only in AML cells. Significantly, only AML cells expressed the cognate receptor of NmU, NMU1R, suggesting the presence of a novel autocrine loop. We examined this possibility in detail. Exogenous NmU "rescued" growth suppression in K562-MERT cells and stimulated the growth of primary AML cells. Short interfering RNA "knockdown" of NmU in K562 cells arrested cell growth. Exposing lndo-1-labeled K562 cells to NmU induced an intracellular Ca ++ flux consistent with engagement of the NMUIR. Combined, these results suggest that NmU expression is related to Myb and that the NmU/NMU1R axis constitutes a previously unknown growth-promoting autocrine loop in myeloid leukemia cells. © 2004 by The American Society of Hematology.
  • Authors

    Published In

  • Blood  Journal
  • Digital Object Identifier (doi)

    Author List

  • Shetzline SE; Rallapalli R; Dowd KJ; Zou S; Nakata Y; Swider CR; Kalota A; Choi JK; Gewirtz AM
  • Start Page

  • 1833
  • End Page

  • 1840
  • Volume

  • 104
  • Issue

  • 6